- Home
- VISN vs ARQT Comparison
VISN vs ARQT Comparison
Compare VISN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VISN | ARQT |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | 4500 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VISN | ARQT |
|---|---|---|
| Price | $19.41 | $24.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $21.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 4.2M | 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $9.44 | $34.85 |
| Revenue Next Year | $5.91 | $29.39 |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $16.50 | $12.42 |
| 52 Week High | $19.91 | $31.77 |
Technical Indicators
Market Signals| Indicator | VISN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 65.30 | 54.33 |
| Support Level | $17.51 | $22.56 |
| Resistance Level | $19.91 | $25.03 |
| Average True Range (ATR) | 0.63 | 0.93 |
| MACD | 0.08 | 0.24 |
| Stochastic Oscillator | 96.18 | 80.23 |
Price Performance
Historical ComparisonAbout VISN Vistance Networks Inc. Common Stock
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.